Capricor Therapeutics shares are trading lower by 6.05% during Thursday's session. The company earlier commenced its public offering of common stock. Market-moving news hits Benzinga Pro first—get a ...
Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the company reported positive top-line results from a late-stage study of ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against ...
Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
We recently compiled a list of 7 Best Russell 2000 Stocks to Buy According to Analysts. In this article, we will look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) ranks among the best Russell ...
Capricor Therapeutics (NASDAQ:CAPR) stock rose 5% in midday trading Friday after the company reported positive long-term data from a study of its drug deramiocel in the treatment of Duchenne muscular ...
Capricor Therapeutics (NASDAQ:CAPR) just reported results for the first quarter of 2024. Capricor Therapeutics reported earnings per share of -31 cents. This was below the analyst estimate for EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results